Turn Therapeutics is a clinical-stage dermatology biotech company whose lead candidate, GX-03, is being evaluated for moderate-to-severe atopic dermatitis and for onychomycosis. GX-03 has generated encouraging investigator-sponsored human data in onychomycosis. The company is conducting a Phase 2 trial in moderate-to-severe atopic dermatitis and expects a mid-year readout from that study. Turn plans to advance its atopic dermatitis and nail fungus programs in parallel and to prepare for potential registrational trials. The recently secured up-to-$25 million growth capital loan facility from Avenue Capital Group is intended to extend the company's runway through key clinical milestones and, if fully utilized, support operations through the end of 2027. No revenue or other operating metrics were disclosed in the articles.

Total raised

$100M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Mar 2026